
OCT 2 5 2002

# Special 510(k) Device Modification: EBI® XFIX® DFS® Fixation System



(973) 299-9300, ext.2208

### 510(k) Summary of Safety and Effectiveness

This 510(k) Summary of Safety and Effectiveness for the EBI® XFIX® DFS® System is provided as required per Section 513(I)(3) of the Federal Food, Drug and Cosmetic Act.

Telephone:

1. Sponsor:

EBI, L.P.

100 Interpace Parkway Parsippany, NJ 07054

Date Prepared: October 7, 2002

2. Proprietary Name:

EBI® XFIX® DFS® System

Common Name:

External Fixation Device

**Classification Name:** 

Single Multiple Component Metallic Bone Fixation

Contact Person: Frederic Testa, RAC

Appliances and Accessories, 21 CFR 888.3030.

# 3. Predicate or Legally Marketed Device:

• EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System (K953406)

## 4. Description of Device:

The System consists of fixation components and implantable bone screws. The EBI® XFIX® DFS® System is utilized in the following manner: bone screws are inserted through the patient's skin and soft tissue, and into the bone. The fixator frame of the EBI® XFIX® DFS® System is attached to the shanks of the bone screws. The intended use and fundamental scientific technology have not changed from the previously cleared submission. This submission is only for the addition of modified self-drilling and blunt-tipped bone screws to the System

#### 5. Intended Use:

The EBI® XFIX® DFS® System is a unilateral external fixation device intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

Ked 3379 Jeld

#### 6. Materials:

The components of the System may be manufactured from materials such as Aluminum, Stainless Steel, Cobalt Chrome, Carbon Fiber, and Titanium Alloy.

# 7. Comparison of the technological characteristics of the device to predicate devices:

The modified EBI® XFIX® DFS® System is substantially equivalent to the following predicate device:

EBI® XFIX® DFS® System (K953406)

- The modified EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System is fabricated from the same materials as the components of the currently marketed EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> Fixation System.
- The modified EBI XFIX® DFS® System and the currently marketed EBI® XFIX® DFS® System are both indicated for the treatment of bone conditions, including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.
- The bone screw clamps of the modified EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System, like the bone screw clamps currently marketed in the EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System, are designed for attachment to the bone screws.
- The additional component of the EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System, like the components of the currently marketed EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System, is provided non-sterile.
- There are no significant differences between the modified EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System and the currently marketed EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System. It is substantially equivalent\* to the predicate device with regard to intended use, materials, and function.

<sup>\*</sup>Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate to whether the product can be lawfully marketed without pre-market approval or reclassification and is not intended to be interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 2 5 2002

EBI, L.P. Frederic Testa, RAC Regulatory Affairs Specialist 100 Interpace Parkway Parsippany, New Jersey 07054

Re: K023399

Trade/Device Name: EBI® XFIX® DFS® System

Regulation Number: 888.3030

Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances and

Accessories

Regulatory Class: Class II

Product Code: KTT Dated: October 8, 2002 Received: October 9, 2002

Dear Mr. Testa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

### Page 2 – Mr. Frederic Testa

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# STATEMENT OF INDICATIONS FOR USE

Page of

510(k) Number (if known):	<b>1111 11 11 11 11 11 11 11 11 11 11 11 1</b>	
Device Name: EBI® XFIX®	DFS <sup>®</sup> System	
Indications For Use:		
The EBI <sup>®</sup> XFIX <sup>®</sup> DFS <sup>®</sup> Syste	em is a unilateral	external fixation device intended for use i
the treatment of bone condition	ons including leg	lengthening, osteotomies, arthrodesis,
fracture fixation, and other bo	one conditions am	enable to treatment by use of the external
fixation modality.		
(PLEASE DO NOT WRITE) IF NEEDED)	BELOW THIS L	INE-CONTINUE ON ANOTHER PAGE
Concurren	ce of CDRH, Off	ice of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use (Optional Format 1-2-96)
$ \int_{C} \frac{C}{(\text{Divis})} $	ion Sign-Off	1 Milkern
V DIVIS:	eurological Dev	Mar wative
	Number	K023399